Barclays lowered the firm’s price target on Amdocs (DOX) to $111 from $113 and keeps an Overweight rating on the shares following the CEO roadshow. The company is phasing out low-margin non-core businesses in a move that management indicated will boost recurring revenue and bring fiscal 2025 operating margin north of 21% while delivering double-digit shareholder return, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DOX:
- Amdocs price target raised to $105 from $98 at Oppenheimer
- Radcom names Benny Eppstein as new CEO, effective December 1
- Amdocs Reports Record Revenue, Eyes Strategic Growth
- Amdocs Limited Reports Record Revenue for Fiscal 2024
- Closing Bell Movers: Instacart down 6% after earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
